摘要
目的:分析2型糖尿病(T2DM)患者采取利拉鲁肽联合甘精胰岛素治疗的临床疗效。方法:选取本院于2016-02-2018-12期间收治的88例T2DM患者,随机分为两组,利拉鲁肽联合甘精胰岛素组作为研究组(n=46),单纯采用甘精胰岛素治疗组作为对照组(n=42),比较两组治疗后空腹血糖(FPG)、餐后2h血糖(2hPG)和糖化血红蛋白(HbAlc)水平变化,甘精胰岛素日用量、血糖达标时间及低血糖发生率。结果:与同组治疗前比较,两组患者治疗后FPG、2hPG、HbAlc水平均降低(P<0.01);研究组治疗后FPG、2hPG、HbAlc、甘精胰岛素日使用剂量均低于对照组,血糖达标时间短于对照组,且低血糖发生率低于对照组,差异均有统计学意义(P<0.01)。结论:利拉鲁肽联合甘精胰岛素联合治疗T2DM临床疗效显著,能改善血糖水平,减少胰岛素用量,缩短血糖达标时间以及降低不良反应发生率,值得临床推广应用。
Objective: To analyze the clinical efficacy of liraglutide combined with insulin glargine in patients with type 2 diabetes(T2DM). Method: Eighty-eight patients with T2DM admitted to our hospital from February 2016 to December 2018 were randomly divided into two groups. The liraglutide combined with insulin glargine group was used as the study group(n=46) and insulin glargine treatment group as the control group(n=42). The levels of fasting blood glucose(FPG), postprandial 2h blood glucose(2hPG), glycosylated hemoglobin(HbAlc), daily dose of insulin glargine, blood glucose compliance time and the rate of hypoglycemia were compared between the two groups. Results: The levels of FPG, 2hPG and HbAlc in the two groups after treatment were lower than those before treatment(P<0.01). The levels of FPG, 2hPG, HbAlc, the daily doses of insulin glargine in study group after treatment were lower than those of the control group, and the blood glucose compliance time was shorter than that of the control group, and also the incidence of adverse reactions was lower than that of the control group(P<0.01). Conclusion: The clinical efficacy of liraglutide combined with insulin glargine in patients with type 2 diabetes is significant. It can help improving blood sugar level, reducing insulin dosage, shortening blood glucose compliance time and reducing the incidence of adverse reactions. It is worthy of clinical application.
作者
李为
柯尊琼
LI Wei;KE Zun-qiong(Department of Pharmacy , People’s Hospital of Hubei University of Medicine, Shiyan 442000 , China)
出处
《微循环学杂志》
2019年第2期55-57,共3页
Chinese Journal of Microcirculation
